Stock KDEV KAROLINSKA DEVELOPMENT AB
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Karolinska Development AB

Equities

KDEV

SE0002190926

Market Closed - Nasdaq Stockholm
Other stock markets
 08:47:16 03/05/2024 pm IST 		5-day change 1st Jan Change
1.58 SEK 0.00% Intraday chart for Karolinska Development AB +4.08% -6.95%
26/04 Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
16/04 Karolinska Development AB Announces That Björn Cochlovius Has Declined Re-Election CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2024
Karolinska Development AB Announces That Björn Cochlovius Has Declined Re-Election
Karolinska Development AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Karolinska Development Portfolio Company AnaCardio Completes SEK150 Million Funding Round
Karolinska Development Takes Part in Portfolio Company Umecrine Cognition's Capital Raise
Karolinska Development AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Modus Therapeutics to Launch SEK40 Million Rights Offering, Issue Shares to Offset SEK20 Million Loan
Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery
Karolinska Development AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Karolinska Unit's Investigational Drug Shows Potential as Anemia Treatment
Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2023
Karolinska Development's Portfolio Company Biosergen Presents Positive Results from Phase 1 Study of Drug Candidate to Treat Systemic Fungal Infection
Karolinska Development AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
Karolinska Development AB Reports Earnings Results for the Full Year Ended December 31, 2022
Karolinska Development AB Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data
Karolinska Development Up 9% as Umecrine Wins US Orphan Drug Tag for Liver Disease Drug Candidate
Karolinska Development AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Karolinska Development Partakes In Danish Dermatology Company Henlez' Seed Financing
Modus Therapeutics AB's Portfolio Company Modus Therapeutics Completes Recruitment in a Clinical Phase 1B Study of Sevuparin
Karolinska Development Appoints New CFO
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KDEV Stock
  4. News Karolinska Development AB
  5. Other languages